Why the study?
Does 6-month cholesterol-lowering therapy with simvastatin improve coronary flow reserve in patients with early stages of coronary atherosclerosis and mild to moderate hypercholesterolemia?
Does 6-month cholesterol-lowering therapy with simvastatin improve coronary flow reserve in patients with early stages of coronary atherosclerosis and mild to moderate hypercholesterolemia?
Six months of simvastatin therapy significantly improves coronary vasodilator capacity and reduces anginal symptoms in patients with early-stage coronary atherosclerosis and mild-to-moderate hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Simvastatin was associated with improved coronary flow reserve; hypothesis-generating and requires randomized confirmation before practice change.
Baller et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: